01st week of 2010 patent applcation highlights part 33 |
Patent application number | Title | Published |
20100003204 | Nanoparticle hybrid sunscreens - The invention discloses and claims a new class of chemical compositions with ideal sunscreen properties. The chemical composition comprises spherical particles between 200 nm and 10 microns in diameter prepared by an emulsion polymerization of tetraalkoxysilanes or organotrialkoxysilanes or organobridged trialkoxysilanes with a dye monomer bearing two or more alkoxysilyl groups attached to the bridging chromophore. The resulting spheres absorb ultraviolet light. The dye can be any organic chromophore capable of receiving multiple trialkoxysilyl groups resulting in multipoint covalent attachment that precludes leaching of the dye from the spheres. The formic acid-toluene-monomer emulsion polymerization allows for large-scale (>100 gram) synthesis of monodisperse particles under acidic, non-aqueous conditions without surfactants. The particles less than 1 micron in diameter are smooth as talc to the touch and will provide a smooth formulation for sunscreen creams or lotions. | 2010-01-07 |
20100003205 | Cosmetic Composition - Cosmetic composition providing a high coverage of skin while retaining a natural skin appearance comprising iron oxide particles having an average primary particle size of less than or equal to 100 nm, iron-containing titanium dioxide particles having an average primary particle size of at least 105 nm and comprising from 1% to 15% iron by weight of the titanium dioxide, and a cosmetically acceptable carrier and its use as a foundation and/or as a composition to correct skin discoloration surrounding the eye. | 2010-01-07 |
20100003206 | Cosmetic Composition Containing A Protein And An Enzyme Inhibitor - The present invention is a cosmetic composition comprising a water-soluble protein-based film-forming agent, the film-forming agent having a tertiary structure capable of undergoing a helix-coil transformation, a protease inhibitor in an amount sufficient to protect the protein on the stratum corneum and a cosmetically acceptable vehicle so that the protease inhibitor prolongs the pulling effect of the film-forming agent. | 2010-01-07 |
20100003207 | Photoprotective compositions comprising photosensitive 1,3,5-triazine compounds, dibenzoylmethane compounds and siliceous s-triazines substituted with two aminobenzoate or aminobenzamide groups - UV-photoprotective, topically applicable cosmetic/dermatological compositions contain:
| 2010-01-07 |
20100003208 | Skin Care Products, As Well As Foods and Beverages Containing 6-O-PUFA Ascorbic Esters - Skin care products which contain as a vitamin C component 6-O-PUFA ascorbates represented by general formula (I): | 2010-01-07 |
20100003209 | Odor Blocking Water-Absorbent Compositions - The present invention leads to odor-preventing water-absorbing compositions comprising at least one water-absorbing polymer and at least one urease inhibitor, the polymer being a polymer bearing acid groups, the acid groups being from 50 to 65 mol % neutralized and the urease inhibitor content being in the range from 0.0001% to 0.1% by weight, based on the composition, to processes for the production of the composition and also to hygiene articles and their production. | 2010-01-07 |
20100003210 | EXTERNAL SKIN AGENT COMPRISING MODIFIED CLAY FOR PREVENTING INFLAMMATION - To provide An external skin agent that prevents onset of atopic skin inflammations and is low irritant to skin, which is characterized by including: 1) clay modified by a compound having a quaternary amino group; and 2) a polymer or copolymer that has a side chain including a structure similar to a biological component. | 2010-01-07 |
20100003211 | ANTIFOULING COATING COMPOSITION AND UNDERWATER STRUCTURE USING THE SAME - An antifouling coating composition comprising (A) 100 parts by weight of a curable organic resin and (B) 1-200 parts by weight of a silicone oil having a polyether, a long-chain alkyl, and an aralkyl group in a molecule is effective over time for preventing the fouling of aquatic organisms to underwater structures. An underwater structure coated with the composition is also provided. | 2010-01-07 |
20100003212 | POLYMERS WITH ANTIMICROBIAL ACTIVITY CONTAINING QUATERNARY AMMONIUM GROUPS - The present invention relates to novel articles and the like, typically exhibiting antimicrobial efficacy which articles contain for example a carrier, a spacer attached to the carrier and one or more quaternary ammonium groups attached directly or indirectly to said spacer. | 2010-01-07 |
20100003213 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION - The present invention relates to the use of nucleoside derivatives of formula Ia | 2010-01-07 |
20100003214 | QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2010-01-07 |
20100003215 | Culturing circular ssDNA viruses for the production of vaccines - The present invention relates to the use of interferon in the in vitro cultivation of animal circular ssDNA virus such as Porcine Circovirus 2 or human TT virus in an animal cell line. | 2010-01-07 |
20100003216 | HCV NS-3 Serine Protease Inhibitors - Compounds of the formula | 2010-01-07 |
20100003217 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections - Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. | 2010-01-07 |
20100003218 | HYBRID-AAV VECTORS TO DELIVER LARGE GENE EXPRESSION CASSETTE - Hybrid adeno-associated virus (AAV) vector systems able to efficiently express therapeutic target genes larger than may be carried in a single AAV vector are provided, wherein a highly recombinogenic foreign DNA sequence is incorporated into two or more ITR-mediated AAV vectors. In one aspect of one embodiment, the novel hybrid AAV vector system is a hybrid dual AAV (hdAAV) vector system. In another aspect of one embodiment, the novel hybrid AAV vector system is a hybrid tri AAV (htAAV) vector system. A method of treating a clinical disease caused at least in part by a defective gene is provided, and comprises (1) providing a hybrid AAV vector system capable of expressing a therapeutic target gene, wherein the therapeutic target gene is capable of replacing, restoring or counteracting the effects of the defective gene; and (2) administering a therapeutic amount of said vector system to a subject wherein said therapeutic target gene is expressed at levels having a therapeutic effect. | 2010-01-07 |
20100003219 | Methods to Increase Transgene Expression From Bacterial-Based Delivery Systems by Co-Expressing Suppressors of the Eukaryotic Type I Interferon Response - Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene. | 2010-01-07 |
20100003220 | AGENTS FOR TREATING MALIGNANT MESOTHELIOMA - The present invention provides an effective therapeutic composition for malignant mesothelioma. Specifically, the present invention provides a therapeutic composition for mesothelioma, comprising a calponin-targeting and tumor-lysing variant of herpes simplex virus (HSV-1), preferably a strain d12.CALPfΔRR. The present invention further provides a method for generating a cell for treating mesothelioma, which comprises infecting mesothelioma cells removed from a patient with an F-type variant of herpes simplex virus proliferating with targeting a calponin gene, preferably a strain d12.CALPfΔRR. Also provided are a cell obtainable by the method, and a calponin-targeting and tumor-lysing variant of herpes simplex virus (HSV-1), preferably a strain d12.CALPfΔRR. | 2010-01-07 |
20100003221 | Medium Supplement for Virus Production - The use of macrolide polyene antibiotics or derivatives or analogues thereof as culture supplement for the propagation of virus is described. Further pharmaceutical compositions comprising a virus and a macrolide polyene antibiotic or a derivative or analogue thereof and methods for using of macrolide polyene antibiotics for transfection and infection of cells as well as the use of macrolide poylene antibiotics for the isolation of virus from clinical samples are disclosed. | 2010-01-07 |
20100003222 | METHODS FOR BONE REGENERATION USING ENDOTHELIAL PROGENITOR CELL PREPARATIONS - The present invention relates in general to orthopedics and to a method for promoting repair of large bone defects, in particular non-union or delayed union fractures. Specifically the invention concerns the use of endothelial progenitor cell preparations for bone repair. | 2010-01-07 |
20100003223 | METHOD FOR THE PRODUCTION OF MULTICOMPONENT STEM CELLS, RELATIVE KITS AND USES IN THE MEDICAL FIELD - The invention relates to a method for the production of multipotent stem cells starting from highly differentiated adult somatic cells of mammals or their precursors comprising the demethylating treatment phase of highly differentiated cells with 5′ Aza 2′ cytidine and relative kits and uses in the medical field. | 2010-01-07 |
20100003224 | Combination Therapy - Methods to mobilize progenitor and/or stem cells from the bone marrow to the bloodstream by administering a combination of at least one CXCR4 inhibitor and at least one VLA-4 inhibitor are described. The combinations may also be used to treat multiple myeloma. | 2010-01-07 |
20100003225 | HSP60, HSP60 PEPTIDES AND T CELL VACCINES FOR IMMUNOMODULATION - The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders. | 2010-01-07 |
20100003226 | Methods and Compositions for Treating Disease - The present invention relates to methods and compositions for treating a subject comprising destroying diseased cells in the subject. The methods comprise obtaining a population of cells from a subject and determining the activity of at least one disease marker gene within the population of the obtained cells. A polynucleotide molecule that encodes a polypeptide that is lethal to the cells is then introduced into the cells, where the expression of the lethal polypeptide is controlled by the promoter of at least one of the disease marker genes previously identified. After introduction of the polynucleotide, the cells are treated with conditions to induce expression of the lethal polypeptide to destroy the cells that are expressing the disease marker gene(s). After destruction of the diseased cells, the remaining live cells, which did not express the lethal polypeptide to an extent necessary to kill the cells, are separated from the dead cells, and the live cells are restored to the subject. | 2010-01-07 |
20100003227 | Brevibacillus Laterosporus Strain Compositions Containing the Same and Method for the Biological Control of Dipters - The invention relates to a new bacterial strain belonging to the genus | 2010-01-07 |
20100003228 | T-CELL VACCINE - An improved T-cell vaccine and methods of making the vaccine are described. The vaccine may be made by stimulating T-cells with all epitopes of an antigenic polypeptide that may be capable of stimulating autoreactive T cells. | 2010-01-07 |
20100003229 | Nuclear telomerase reverse transcriptase variant - The present invention is directed to a novel variant of human telomerase reverse transcriptase (S16AhTERT), which displays properties distinct from those of wildtype telomerase reverse transcriptase. Accordingly, the amino acid sequence of S16AhTERT and nucleic acid sequences encoding same are presented herein, as are methods of use thereof. | 2010-01-07 |
20100003230 | tRNA SYNTHETASE FRAGMENTS - The present invention relates to compositions and methods for treating conditions associated with angiogenesis. In particular the present invention relates to multi-unit complexes of tRNA synthetase fragments and uses thereof; diverse multi-unit complexes including a tRNA synthetase fragment; compositions and methods for modulating angiogenesis; polynucleotides encoding tRNA synthetase fragments and uses thereof; antibodies and epitopes specific to tRNA synthetase fragments; variants of tRNA synthetase fragments and uses thereof; methods for treating angiogenesis; methods for screening for anti-angiogenic agents; methods of modulating angiogenesis; kits for modulating angiogenesis; and business methods for modulating angiogenesis. Preferably the tRNA synthetase fragments are tryptophanyl tRNA synthetase fragments, and more preferably human tryptophanyl tRNA synthetase fragments. | 2010-01-07 |
20100003231 | POLYMERS OF FLUORINATED MONOMERS AND HYDROCARBON MONOMERS - It is provided an implantable device including a polymer blend that contains a polymer formed of fluorinated monomers and hydrocarbon monomers and another biocompatible polymer. | 2010-01-07 |
20100003232 | INSULIN-DEGRADING ENZYME MUTANTS AND METHODS OF USE - Disclosed are mutant polypeptides of insulin degrading enzymes having at least 95% amino acid identity to SEQ ID NO: 1, having at least one mutation in a region corresponding to human IDE-N or human IDE-C, having increased activity, polynucleotides encoding the polypeptides, and methods of use. | 2010-01-07 |
20100003233 | Compositions and methods for treatment of microbial infections - The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions. | 2010-01-07 |
20100003234 | Cellulases, Nucleic Acids Encoding Them and Methods for Making and Using Them - This invention relates to molecular and cellular biology and biochemistry. In one aspect, the invention provides polypeptides having cellulase activity, e.g., endoglucanase, cellobiohydrolase, mannanase and/or β-glucosidase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides cellulase activity, e.g., endoglucanase, cellobiohydrolase, mannanase and/or β-glucosidase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural, food and feed processing and industrial contexts. | 2010-01-07 |
20100003235 | ORAL FORMULATIONS FOR ENTERIC DISORDERS AND/OR REHYDRATION - The present invention relates, generally, to oral formulations including one or more recombinantly-produced human milk proteins. The formulations of the present invention may be used to prevent the onset of diarrhea in patients who have been or will be exposed to one or more agents known to cause diarrhea, and to prevent the recurrence of diarrhea in a patient recovering therefrom. The formulations may also be used in the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. The formulations may also be beneficially administered in accordance with methods for promoting the development of healthy intestinal flora in a human patient. | 2010-01-07 |
20100003236 | USE OF C-GLYCOSIDE DERIVATIVES AS PRO-DESQUAMATING ACTIVE AGENTS - A cosmetic use of at least one C-glycoside derivative in a composition comprising a physiologically acceptable medium, as a cosmetic agent for promoting the desquamation of the skin and/or the scalp and/or for stimulating epidermal renewal. | 2010-01-07 |
20100003237 | In vivo temporal control of activatable matrix-degrading enzymes - Methods and combinations are provided for controlling the duration of action, in vivo, of matrix-degrading enzymes. The methods and combinations permit temporary in-vivo activation of matrix-degrading enzymes upon administration to the extra cellular matrix (or “ECM”). Matrix-degrading enzymes having a controlled duration of action can be used to treat ECM-mediated diseases or disorders characterized by increased deposition or accumulation of one or more ECM components. | 2010-01-07 |
20100003238 | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions - Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders. In one example, the products include an additional agent or treatment. Such products can be used in methods for administering the products to treat the hyaluronan-associated diseases and conditions, for example, hyaluronan-associated cancers, for example, hyaluronan-rich tumors. The methods include administration of the hyaluronan degrading enzyme composition alone or in combination with other treatments. Also provided are methods and compositions for providing sustained treatment effects in hyaluronan-associated diseases and conditions. | 2010-01-07 |
20100003239 | ANTI-HEDGEHOG ANTIBODIES - The invention relates to anti-hedgehog antibodies, their use in the detection of hedgehog expression in tissue, and to the use of such detection in the treatment of cancer. | 2010-01-07 |
20100003240 | CANCER TREATMENT WITH ENDOTHELIN RECEPTOR ANTAGONISTS - The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation. | 2010-01-07 |
20100003241 | Agents for treatment or prevention of an allergic disorder - The present invention relates to agents capable of treating or preventing an allergic disorder in an animal and a method of screening for these agents. In particular, the present invention relates to an isolated nucleic acid molecule comprising (a) an isolated nucleic acid molecule whose expression is modulated in a mammal suffering from or at elevated risk of developing an allergic condition, such that the level of expression of the nucleic acid differs from that in a mammal which is not suffering from or at elevated risk of developing the allergic condition, in which the nucleic acid comprises a sequence selected from the group consisting of sequences identified by probes 243610 at on human chromosome 9q21.13 at locus 138255, 1556097 at on human chromosome 15q25.2 and 242743 at on human chromosome 16p12.1 respectively, or (b) an isolated nucleic acid molecule which is the complement of the nucleic acid of (a), or (c) an isolated nucleic acid molecule which hybridizes under stringent conditions to the nucleic acid of (a) or (b). | 2010-01-07 |
20100003242 | COMPOSITIONS AND METHODS FOR BINDING SPHINGOSINE-1-PHOSPHATE - The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P. | 2010-01-07 |
20100003243 | Uses and Compositions for treatment of Psoriasis and Crohn's Disease - The invention provides methods, uses and compositions for the treatment of psoriasis or Crohn's disease. The invention describes methods and uses for treating psoriasis or Crohn's disease, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat psoriasis in a subject. The invention includes methods of improving patient reported outcomes using a human TNFα antibody, or antigen-binding portion thereof, for the treatment of Crohn's or psoriasis. The invention also provides methods of improving fatigue or depression in patients having Crohns'. | 2010-01-07 |
20100003244 | AGENTS WHICH BIND TO EPITOPES OF GLYCOPROTEIN VI - The present invention provides anti-thrombotic agents, methods for screening for said anti-thrombotics agents and methods of treating thrombotic and other cardiovascular disorders. | 2010-01-07 |
20100003245 | Remedy for Renal Disease - When an anti-human BMP antibody was added to cells of an immortalized human mesangial cell line cultured in the presence of human BMP, the anti-human BMP antibody significantly suppressed the production of type IV collagen in mesangial cells. A number of signaling pathways are involved in abnormal proliferation of type IV collagen. It was therefore completely unpredictable whether merely blocking the BMP signal would indeed suppress the abnormal proliferation of type IV collagen. However, for the first time, the present inventors demonstrated that anti-BMP antibodies are very effective in suppressing the abnormal proliferation of type IV collagen. Thus, anti-BMP antibodies can be used as novel therapeutic agents for kidney diseases associated with abnormal proliferation of the mesangial matrix. | 2010-01-07 |
20100003246 | Novel heterocyclic compounds and uses therof - New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer. | 2010-01-07 |
20100003247 | ASSAY FOR METASTATIC COLORECTAL CANCER - This invention relates, e.g., to a method for predicting the prognosis, the likelihood of metastasis in, or the desirability of administering an aggressive therapy to, a subject with colorectal cancer, comprising determining, in a sample from the subject, the level of phosphorylation compared to a positive and/or negative reference standard, of one or more of: (a) AKT (S473); (b) BAD (S112); (c) cABL (T735); (d) ERK (T42/44); (e) MARCKS (S152-156); (0 p38MAPK (T180-182): (g) STAT 1 (Y701 ); (h) PTEN (S380); (i) EGFR (Y992); (j) PAK 1/2 (S 1 19/204); or (k) PKC zeta/lambda (T410-403); or the total amount of (1) COX-2 protein; wherein if the level of phosphorylation of one or more of a-i or the total amount of COX-2 protein (1) is elevated compared to the negative reference standard, and/or if the level of phosphorylation of j or k is decreased compared to the positive reference standard, the subject has poor prognosis, is likely to undergo metastasis, and/or is a good candidate for aggressive therapy. Also described are methods for treating subjects likely to develop metastatic colorectal carcinoma, and pharmaceutical compositions and kits for implementing methods of the invention. | 2010-01-07 |
20100003248 | POLYPEPTIDE CONSTRUCTS FOR RECTAL AND/OR VAGINAL ADMINISTRATION - The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. | 2010-01-07 |
20100003249 | POLYPEPTIDE CONSTRUCTS FOR TOPICAL ADMINISTRATION - The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. | 2010-01-07 |
20100003250 | (2-ARYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)MORPHOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES - The invention relates to 2-aryl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds of the Formula I: | 2010-01-07 |
20100003251 | Uses of IL-23 Agonists and Antagonists; Related Reagents - Provided are methods of treatment for tumors. In particular, methods are provided for modulating activity of a cytokine molecule and its receptor. | 2010-01-07 |
20100003252 | BLOCKING IMMUNE RESPONSE TO A GRAFT - The present application describes methods for blocking immune response to foreign antigens in a mammal using antagonists which bind to CD20. | 2010-01-07 |
20100003253 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREFOR - The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Epidermal Growth Factor Receptor. It further relates to single domain antibodies that are | 2010-01-07 |
20100003254 | Antibody Substituting for Function of Blood Coagulation Factor VIII - The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII. | 2010-01-07 |
20100003255 | GENE EXPRESSION PATTERN PREDICTIVE FOR COLORECTAL CARCINOMAS - The present invention relates to a micro-array for the prediction of a lymph node metastasis in connection with colorectal carcinoma. The invention further relates to an ex vivo method for predicting a lymph node metastasis in connection with colorectal carcinoma as well as an inhibitor or a modulator suited to treat the metastasing colorectal carcinoma. | 2010-01-07 |
20100003256 | Use of TGF-Beta Antagonists in Treatment of Parathyroid-Related Disorders - The present invention relates to the use of TGF-β antagonists for the treatment, amelioration, and diagnosis of parathyroid-related disorders, e.g., HPT-JT, familial isolated primary hyperparathyroidism (FIPH), and hyperparathyroidism-jaw tumor (HPT-JT) syndrome, as well as its attendant complications. The present invention also relates to the use of modulators of HRPT2 and its related PAF1 complex for the treatment, amelioration, and diagnosis of TGFβ-related disorders, e.g., pulmonary hypertension, cancer, hypertension, fibrosis, wound healing. Assays of the identification of modulators of HRPT2/PAF1 and SMAD/TGFβ are also provided. | 2010-01-07 |
20100003257 | Diagnosis of nasopharyngeal carcinoma and suppression of nasopharyngeal carcinoma invasion - A diagnostic method for NPC based on the activation level of the Gα | 2010-01-07 |
20100003258 | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS - Monoclonal antibodies that bind and inhibit activation of fibroblast growth factor receptor 3 (FGFR3) are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of FGFR3. | 2010-01-07 |
20100003259 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN - The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. | 2010-01-07 |
20100003260 | PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS - The present invention relates to compounds of general formula (I): wherein: R | 2010-01-07 |
20100003261 | AGONIST ANTI-TRK-C MONOCLONAL ANTIBODIES - The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention andior treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy. | 2010-01-07 |
20100003262 | THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC AGENTS FOR HEPATITIS B - The present invention provides regulation of expression of toll-like receptors by the hepatitis B (HBV) pre-core protein, or its extracellular expression product the hepatitis B E antigen (HbeAg). Compounds regulating such expression have use in the treatment and prophylaxis of HBV infection in animal. The invention also provides methods for diagnosing HBV and agents useful in diagnostic protocols. The present invention further contemplates methods for monitoring disease states in humans and other animal species, including animal models, and providing an indication of the subject for infection by HBV, or development of other diseased states. | 2010-01-07 |
20100003263 | MONOCLONAL ANTIBODIES TO ANTHRAX PROTECTIVE ANTIGEN - The characterization and isolation of F20G75, F20G76 and F20G77, anti-PA monoclonal antibodies which also have neutralizing activities is described. The monoclonal antibodies may be used as a pharmaceutical composition for treating individuals suspected of or at risk of or having a | 2010-01-07 |
20100003264 | Reduction of Ophthalmalogic Neovascularization - The present invention generally relates to methods for treatment of neovascularization in various tissues of a patient's eye. One aspect of the invention is a method of treating a patient for ophthalmologic neovascularization by administering an anti-interleukin-10 agent to the eye of a patient in need thereof to decrease the amount of interleukin-10 in the eye. Another aspect of the invention is a method of treating a patient for ophthalmologic neovascularization by administering isolated macrophages to the eye of a patient in need thereof to decrease a volume of a neovascularization complex within the treated eye. | 2010-01-07 |
20100003265 | Isolation, expansion and uses of tumor stem cells - Disclosed are methods for isolating cell populations enriched in tumor stem cells (cancer stem cells), and isolated cell populations substantially enriched in cancer stem cells that are tumorigenic in vivo. Also provided are new methods of tumor diagnosis and classification and personalized methods of treatment for subjects with tumors, based on the availability of populations of cancer stem cells derived from the subject's tumor using the disclosed methods. | 2010-01-07 |
20100003266 | TARGETED IMMUNE CONJUGATES - Disclosed herein are materials and methods related to vaccines. Materials and methods for delivery of immunogens to the reticuloendothelial system via non-circulating lymphoid cells are provided. | 2010-01-07 |
20100003267 | ANTI-ANGIOGENIC COMPOUNDS - The present invention provides VEGF binding peptides. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules. Various uses of the peptides and compounds are provided, including methods to treat disorders associated with abnormal angiogenesis. | 2010-01-07 |
20100003268 | Therapy of Malignant Neoplasias - The present invention provides a 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine for the preparation of a pharmaceutical composition for the treatment of malignant neoplasia. Moreover, the invention provides a method for the treatment of malignant neoplasia, the method comprising the steps of administering 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine to a subject in need thereof and a pharmaceutical composition comprising 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine. | 2010-01-07 |
20100003269 | METHODS AND USES OF CAULIFLOWER AND COLLARD FOR RECOMBINANT PROTEIN PRODUCTION - The present invention relates to a method for the generation of transgenic | 2010-01-07 |
20100003270 | WHOLE BLOOD CULTURES COMPRISING STIMULATED IMMUNE CELLS, AND USE THEREOF AS MEDICAMENTS - The present invention relates to a whole-blood culture containing specific immunocompetent killer cells that are activated against tumor cells, viruses, bacteria and/or allergens, whereby the whole-blood culture consists of whole-blood and a culture medium at a ratio of 3:1 to 4:1, whereby the culture medium has an oxygen excess of at least 100% or more and contains a water-soluble emulsification product comprising a mixture of phospholipids, vitamin E, and low-molecular proteoglycans with a molecular weight of 1,200 to 12,000 Dalton, and whereby dead tumor cells or fragments thereof and/or viral and/or bacterial antigens and/or allergens have been added to the whole-blood culture [to serve] as antigen in the specific recognition process for production of the activated killer cells (stimulation). The invention also relates to a method for producing the culture, as well as stimulants for the whole-blood culture and a method for the selection thereof. | 2010-01-07 |
20100003271 | NITRIC OXIDE INCREASES SWITCHING OF T CELLS INTO T REGULATORY CELLS - An ex vivo method of expanding a population of regulatory T-cells includes culturing a starting population of cells containing CD4 | 2010-01-07 |
20100003272 | Method for Expanding Monocytes - The invention relates to an ex vivo method for expanding monocytes, macrophages or dendritic cells, which method comprises inhibiting the expression or the activity of MafB and c-Maf in monocytes, macrophages or dendritic cells; and expanding the cells in the presence of at least one cytokine or an agonist of cytokine receptor signaling. | 2010-01-07 |
20100003273 | NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION - The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection. | 2010-01-07 |
20100003274 | FERMENTED COMPOSTIONS HAVING IMMUNODULATORY ACTIONS - Novel compositions are provided that exhibit immunomodulatory actions such as an immunostimulating action and an anti-allergic action. Compositions are provided in which Kombu fermented with lactic acid bacteria is contained either alone or in combination with sesame and soybean(s) that have been fermented with lactic acid bacteria. The compositions enable nutrients to be absorbed in a balanced way, feature high safety, and have superior immunomodulatory actions. | 2010-01-07 |
20100003275 | Immunostimulatory Composition comprising Lipoprotein in Microalgae Extract - Potent immunostimulatory lipoproteins have been identified within the following microalgae and extracts thereof: | 2010-01-07 |
20100003276 | Methods for treating anthrax and inhibiting lethal factor - This invention relates to a method of inhibiting lethal factor (LF) or for treating anthrax and other conditions related to anthrax infection comprising co-administration of an effective amount of an LF inhibitor and a vaccine to a patient in need of such treatment. Such co-administration unexpectedly provides an effective immune response. | 2010-01-07 |
20100003277 | VACCINES AND IMMUNOTHERAPEUTICS USING CODON OPTIMIZED IL-15 AND METHODS FOR USING THE SAME - Nucleic acid molecules that encode IL-15 or fragments thereof, which express protein at a higher level than nucleic acid molecules with native coding sequences for IL-15 are disclosed. Nucleic acid molecules with additional modifications such as the absence of coding sequences for IL-15 signal sequences and/or the absence of IL-15 untranslated sequences and/or inclusion of non-IL-15 signal sequences are also disclosed. Vectors, including plasmids and viral vectors, comprising such nucleic acid molecules; and to host cells comprising such nucleic acid molecules are disclosed as well as methods of using such nucleic acid molecules alone or in combination with nucleic acid sequences encoding immunogens which are part of the nucleic acid molecules and/or part of a different nucleic acid molecule. Recombinant vaccines and live attenuated pathogens encoding fusion proteins, and methods of using the same, are disclosed. | 2010-01-07 |
20100003278 | Immunological Compositions Effective for Lessening the Severity or Incidence of PRRSV Signs and Methods of Use Thereof - The present application describes improved an immunogenic compositions of virus vaccines wherein the virus vaccines comprise adjuvants selected from the group consisting of MCP-1, | 2010-01-07 |
20100003279 | VACCINE FOR IN OVO INOCULATION - A purpose of the present invention is to provide a vaccine for in ovo inoculation effective for prevention of any fowl viral diseases. A fowl vaccine for in ovo inoculation with high efficacy in view of safety as well wherein, by holding such live viruses on a virus-adsorbing agent through adsorption that have been difficult for practical usage as a vaccine for in ovo inoculation, viral growth in embryonated chicken eggs after in ovo inoculation is retarded to thereby reduce pathogenicity of the viruses to embryo to avoid reduction in hatching rate and to alleviate severity in clinical symptoms after hatching. A virus-adsorbing agent to be used in the vaccine includes an aluminum compound such as aluminum hydroxide gel, potassium alum and the like. | 2010-01-07 |
20100003280 | Adjuvant compositions - Adjuvant compositions comprising type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described. | 2010-01-07 |
20100003281 | MONOCLONAL ANTIBODY AGAINST HEPATITIS E VIRUS OR ITS FRAGMENT WITH BINDING ACTIVITY AND USE THEREOF - The present invention relates to monoclonal antibody specifically binding to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF2 or its conserved variants or its active fragments, or other monoclonal antibodies against ORF2 which can cross react with said monoclonal antibody of present invention, and its nucleotide sequence or its degenerate sequence; to the antigenic determinant in hepatitis E virus ORF2; to a method for screening isolated or recombined polypeptide or polypeptide analog, which has the same property of specifically binding said monoclonal antibody 8C11 and/or 8H3 as said antigenic determinant 1) or 3) of hepatitis E virus ORF2; to polypeptide or polypeptide analog screened by the method above and its nucleotide sequence or degenerate sequence; to a use of said polypeptide or polypeptide analog in preparation of a medicament for the diagnosis and/or precaution of hepatitis E virus infection; to a diagnostic kit for hepatitis E virus infection and a vaccine composition for prophylaxis of hepatitis E virus infection; to use of said monoclonal antibodies or their active fragments or conserved variants in preparation of a medicament for diagnosis, prophylaxis and/or treatment of hepatitis E virus infection; to pharmaceutical composition for prophylaxis and/or treatment of hepatitis E virus infection and a method for prophylaxis and/or treatment of hepatitis E virus infection; to a recombinant expression vector comprising said nucleotide molecule in present invention and a host cell transformed with said recombinant expression vector that is able to express monoclonal antibody and its conserved variants or active fragments or polypeptide or polypeptide analogs. | 2010-01-07 |
20100003282 | SYSTEMS AND METHODS FOR DELIVERY OF A THERAPEUTIC AGENT - Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems. | 2010-01-07 |
20100003283 | LIPID A DEFICIENT MUTANTS OF NEISSERIA MENINGITIDIS - The invention provides lipid A deficient mutant | 2010-01-07 |
20100003284 | Live attenuated aldolase-negative bacterial vaccine - A live attenuated bacterium of the genus | 2010-01-07 |
20100003285 | Human Hookworm Vaccine - A vaccine for human hookworm is provided. The vaccine comprises at least one L3 larval stage antigen (e.g. Na-ASP-2 or Na-SAA-2) and at least one adult stage human hookworm antigen (e.g. Na-APR-1, Na-CP-2, Na-CP-3, Na-CP-4, Na-CP-5, or Na-GST-1) and adjuvants. | 2010-01-07 |
20100003286 | PHARMACEUTICAL PRODUCT COMPRISING TISSUE OF THE MALE VEGETAL REPRODUCTIVE SYSTEM - The present invention discloses pharmaceutical products useful for the treatment of allergies, autoimmune diseases, vaccination of mammals, as well as for in vitro diagnostics. These products preferably comprise pollen grains having altered protein composition by means of genetic modification in the plant that produces them. The production process of the present invention comprises the cultivation of genetically modified plants capable of producing pollen grains having modified molecular composition. | 2010-01-07 |
20100003287 | Compositions and Methods Relating to Treatment of Cancer and Infectious Diseases - The present invention provides methods for modulating an immune response by administering a composition comprising a Toll-like receptor agonist and an immune mediator which downregufates the expression of the anti-inflammatory cytokine IL-10 and upregulates the expression of the pro-inflammatory cytokine IL-12. The methods can be used to provide therapeutic treatment for cancerous conditions and infectious diseases. | 2010-01-07 |
20100003288 | CpG DNA Adjuvant in Avian Vaccines - A CpG DNA adjuvant in avian vaccines is disclosed, which includes an immunostimulatory oligodeoxynucleotide (ODN) having a plurality of TCG tandem repeats at a 5′end, a poly-G structure at a 3′ end, and at least one unmethylated CpG motif with avian specific flanking sequences at two ends thereof between the 5′ end and the 3′ end. The CpG DNA adjuvant in avian vaccines is advantageous to carry out large-scale production, specifically enhance avian innate and adaptive immune responses, and the CpG DNA adjuvant is hardly to be digested by DNase due to its particular structures. | 2010-01-07 |
20100003289 | Controlled Release Complex Formulation For Oral Administration of Medicine For Diabetes and Method For The Preparation Thereof - A controlled release combination formulation for oral administration comprising a) a controlled release portion containing metformin or a pharmaceutically acceptable salt thereof as an active ingredient, and a combination of a polyethylene oxide and a natural gum as a carrier for controlled release; and b) a rapid-release portion containing a sulfonylurea-based medicine for treating diabetes as an active ingredient coated on the controlled release portion is useful for the treatment of diabetes, for it is capable of maintaining an effective concentration of the medicines in blood at a constant level. | 2010-01-07 |
20100003290 | OIL AND WATER REPELLENT COSMETIC POWDER AND METHODS OF MAKING AND USING SAME - Disclosed is a coated powder that comprises a powder substrate having a coating thereon that includes a 2-(perfluoroalkyl)ethyl alcohol phosphate of the formula | 2010-01-07 |
20100003291 | NANO-PARTICLES FOR COSMETIC APPLICATIONS - Micro and/or nano-particles are fabricated in micro and/or nano-scale cavities of replicate molds for cosmetic applications. The micro and/or nano-particles can be fabricated for inclusion in cosmetic composition or fabricated from cosmetic ingredients. | 2010-01-07 |
20100003292 | FINE-GRANULOMETRY FUNGAL EXTRACT CHITINE-GLUCANE - The present invention relates to a chitin-glucan copolymer in the form of micrometric particles. | 2010-01-07 |
20100003293 | Processes for Reducing the Appearance of Pastiness or Ashiness on Skin - Processes for reducing the appearance of ashiness or pastiness on skin by applying thereto a cosmetic composition comprising transparent iron oxide particles, iron-containing titanium dioxide particles, and a cosmetically acceptable carrier. These processes are useful to provide coverage of skin imperfections and/or skin tonal variations and/or skin discoloration surrounding the eyes on different types of skin, while, at the same time, retaining a natural skin appearance. | 2010-01-07 |
20100003294 | PATCH DEVICE FOR A FRAGRANCE AND METHOD OF USING THE PATCH DEVICE - A patch device that includes a backing layer which is a barrier to at least a fragrance, a reservoir layer, which is attached to the backing layer and serves for holding a volume of one or more fragrances, and a cover layer for covering the reservoir layer when filled with fragrance. The cover layer is permeable to vapour from at least one fragrance, which cover layer in a first position of the patch device, in which the reservoir layer is free of fragrance, is situated at least partly offset or dislocated from the reservoir layer, and which cover layer in a second position of use, in which the volume of one or more fragrances has been delivered to the reservoir layer, covers the reservoir layer. Support sheets, which support the backing layer, and a flap part of the cover layer, serve as a tool for applying the flap part into covering relationship to cover or encapsulate the reservoir layer. | 2010-01-07 |
20100003295 | Nonabrasive Sensory Exfoliating System - The present invention relates to a method of exfoliating and warming the skin comprising the steps of topically applying a cosmetic or pharmaceutical composition. The composition comprises a physical exfoliating system of at least three insoluble particles of different materials, a heat generating agent and a silicone component. | 2010-01-07 |
20100003296 | MANUFACTURING METHODS AND APPLICATIONS OF ANTIMICROBIAL PLANT FIBERS HAVING SILVER PARTICLES - The present invention also provides a method for making the antimicrobial plant fibers. The characteristic of the method is no need of additional reducing agent. The present invention provides plant fibers with antimicrobial effects. The antimicrobial antifungal effect of the fibers is derived from nanosilver particles (diameter between 1 and 100 nm) which are attached to the fibers. The fibers which are made of cotton, linen, blending fibers, or any combination thereof. The fibers can be used to make yarn cloth to be used particularly for treating patients with burns or wound. The cloth made from the antimicrobial fibers can be further used to make clothes such as underwears, socks, shoe cushions, shoe linings, bed sheets, pillow cases, towels, women hygiene products, laboratory coats, and medical robes. | 2010-01-07 |
20100003298 | SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDER PERIOD OF TIME - Subcutaneous implants obtained by extrusion containing ( | 2010-01-07 |
20100003299 | RNAi Methods and Compositions for Stimulating Proliferation of Cells with Adherent Functions - Described herein are methods and compositions for stimulating proliferation of cells that express adherent junctions and cease proliferation, for example, human corneal endothelial cells, by downregulation of certain cell-cell junctions. In one embodiment, downregulation is achieved using RNA interference, and contacting the cells with mitogenic growth factors and an agent that elevates intracytoplasmic cAMP. Furthermore, described herein are methods of isolating human corneal endothelial cells from keratocytes, and methods of preserving and maintaining viability of human corneal endothelial cell aggregates. Also described are surgical grafts comprising human corneal endothelial cells that have been isolated, optionally stored, and transiently contacted with an agent that downregulates expression of p 120, and a biocompatible support. The methods and compositions described herein can be used in novel therapies to help expand human corneal endothelial cells during in vitro tissue engineering and for in vivo treatment of corneal endothelial dysfunction. | 2010-01-07 |
20100003300 | INJECTABLE DELIVERY OF MICROPARTICLES AND COMPOSITIONS THEREFORE - Compositions and methods of making and using of microparticle compositions that provide faster flow or improved injectability through smaller or small-diameter needles have been developed. Notably, the microparticle compositions can be successfully delivered or administered through smaller-diameter needles than other microparticle compositions prepared from biocompatible or biodegradable polymers including, for example, poly(lactide), poly(lactide-co-glycolide), polycaprolactone, or poly-3-hydroxybutyrate. The microparticle compositions can exhibit a higher solids loading for a given needle size and/or faster flow through needles than other microparticle compositions. Further, blending or mixing the polymer of the microparticle composition with other polymer formulations can enhance the injectability of the resulting formulation. | 2010-01-07 |
20100003301 | Bone Defect Filler, Release-Controlled Carrier, And Their Production Methods - A bone filling material having controlled release of a pharmaceutical agent such as a growth factor, and a drug release controlling carrier having controlled release of a pharmaceutical agent is provided by inactivating a functional group which can strongly bind to the pharmaceutical agent of the bone filling material with a blocking agent. The bone filling material and the drug release controlling carrier of the present invention comprises: a calcium-based material such as hydroxyapatite, carbonate apatite, fluorapatite, chlorapatite, β-TCP, and α-TCP; a blocking agent of the calcium-based material such as serine and dextran; and a pharmaceutical agent. | 2010-01-07 |
20100003302 | VASCULAR RESTENOSIS PREVENTING AGENT AND IMPLANTABLE INTRAVASCULAR DEVICE COATED THEREWITH - A drug for preventing vascular restenosis comprises a compound that inactivates α1-protease inhibitor and α2-macroglobulin as active constituents, which are associated with occurrence of vascular restenosis after coronary artery intervention. Preferably, the drug is coated on a surface of an implantable intravascular device and locally administered to the affected area by application of the implantable intravascular device to a narrowed area. | 2010-01-07 |
20100003303 | POLYMERS OF FLUORINATED MONOMERS AND HYDROCARBON MONOMERS - It is provided a method of treating a disorder, the method comprising implanting in a patient an implantable device including a polymer formed of fluorinated monomers and hydrocarbon monomers and another biocompatible polymer. | 2010-01-07 |
20100003304 | METHOD OF IMPROVING THE OSTEOINDUCTIVITY OF CALCIUM PHOSPHATE - The invention relates to methods of improving the osteoinductivity of calcium phosphate materials, to calcium phosphate materials having improved osteoinductivity as well as bone (re)generation scaffolds produced therefrom and to the use of such materials and scaffolds in methods of treatment. | 2010-01-07 |